Cultivating cohort studies for observational translational research

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 4, 2013, Pages 481-484

  Ransohoff, David F ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; DNA; MOLECULAR MARKER; RNA;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER SURGERY; CLINICAL PRACTICE; COLON CANCER; DNA DETERMINATION; FECES ANALYSIS; HEALTH MAINTENANCE ORGANIZATION; HUMAN; OBSERVATIONAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; TRANSLATIONAL RESEARCH;

BIOMEDICAL RESEARCH; COHORT STUDIES; CONTROLLED CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; OBSERVATION; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84876565335     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0140     Document Type: Article

References (15)

1. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol 2010;172:517-24.
2. Micheel C, Nass SJ, Omenn GS, editors. Evolution of translational omics: lessons learned and the path forward. Washington, DC: Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials; Board on Health Care Services; Board on Health Sciences Policy; Institute of Medicine; 2012.
3. Ioannidis JP, Khoury MJ. Improving validation practices in "omics" research. Science 2011;334:1230-2.
4. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-9. (Pubitemid 40310279)
5. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007;60:1205-19. (Pubitemid 350061148)
6. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 2010;28:698-704.
7. Khoury MJ, et al. TBA. Transforming Epidemiology for 21st Century Medicine and Public Health. Cancer Epidemiol Biomarkers Prev 2013;22:508-17.
8. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-26. (Pubitemid 40051905)
9. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7. (Pubitemid 34178440)
10. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72. (Pubitemid 351302552)
11. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005;97:315-9. (Pubitemid 40310281)
12. McIntosh M, Anderson G, Drescher C, Hanash S, Urban N, Brown P, et al. Ovarian cancer early detection claims are biased. Clin Cancer Res 2008;14:7574.
13. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res 2011;4:375-83.
14. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351:2704-14. (Pubitemid 39665324)
15. Bretthauer M. The NordICC clinical trial; 2010 [Accessed 2010April 12]. Available from:"http://www.clinicaltrials.gov/ct2/show/NCT00883792? term1/4bretthauer&rank1/42.